|Series A, 8/06 |
Queen City Angels
Kentucky Seed Capital Fund
Kentucky Science and Technology Corporation
RhinoCyte engages in the development and commercialization of diagnostic tools and therapies for stem cell treatment of multiple degenerative and traumatic neurological diseases. Its technology facilitates functional recovery in patients, including therapeutic stem cell transplantation with cells from the patient’s own nasal cavity eliminating the need for immunosuppressive therapy. The companyâ€™s technology is used to treat conditions, such as Parkinson’s disease, Multiple Sclerosis, Alzheimer’s disease, and spinal cord injuries. RhinoCyte, Inc. was founded in 2005 and is based in Louisville, Kentucky.